RxDoctor Payments Data

Yelena Popova

Physician Assistant · Sacramento, CANPI 1821061680

Payments from drug & device makers

$3,137in general payments, 2019–2025

Across 149 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$515
  • Novo Nordisk$464
  • Lilly USA, LLC$274
  • Boehringer Ingelheim$242
  • GSK$226
  • Pfizer$212
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,130100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,137 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$57,901
JardianceEmpagliflozin48$52,942
EliquisApixaban58$45,744
LinzessLinaclotide47$40,476
JanuviaSitagliptin Phosphate18$25,355
RybelsusSemaglutide16$24,226
CreonLipase/Protease/Amylase27$22,909
TrulicityDulaglutide14$21,640
TradjentaLinagliptin23$17,341
MyrbetriqMirabegron12$13,393
XareltoRivaroxaban17$10,136
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$7,364
SymbicortBudesonide/Formoterol Fumarate21$6,823
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$5,488
Atorvastatin Calcium323$3,952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$464$82,12876 claims
Boehringer IngelheimJardiance, Tradjenta, Pradaxa$242$72,14682 claims
AbbVieLinzess, Creon, Synthroid$515$65,482100 claims
PfizerEliquis$212$45,74458 claims
MerckJanuvia$18$25,35518 claims
Lilly USA, LLCTrulicity$274$21,64014 claims
Johnson & JohnsonXarelto$110$10,13617 claims
AstraZenecaSymbicort$46$6,82321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →